APLT stock icon

Applied Therapeutics
APLT

$5.55
4.65%
 

About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Employees: 26

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

2,571% more call options, than puts

Call options by funds: $45.8M | Put options by funds: $1.71M

210% more capital invested

Capital invested by funds: $206M [Q4 2023] → $639M (+$433M) [Q1 2024]

100% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 6 (+3) [Q1 2024]

100% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 17

35% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 23

10% more funds holding

Funds holding: 81 [Q4 2023] → 89 (+8) [Q1 2024]

9.19% more ownership

Funds ownership: 79.55% [Q4 2023] → 88.74% (+9.19%) [Q1 2024]

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
26%
upside
Avg. target
$11.33
104%
upside
High target
$13
134%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
RBC Capital
Brian Abrahams
116%upside
$12
Outperform
Reiterated
11 Apr 2024
RBC Capital
Brian Abrahams
116%upside
$12
Outperform
Initiated
26 Mar 2024
UBS
Esther Rajavelu
134%upside
$13
Buy
Maintained
15 Mar 2024
UBS
Esther Rajavelu
116%upside
$12
Buy
Maintained
6 Mar 2024
Leerink Partners
Joseph Schwartz
116%upside
$12
Outperform
Initiated
22 Feb 2024

Financial journalist opinion